REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 174 filers reported holding REATA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $666,207 | +113200.5% | 6,534 | +0.9% | 0.00% | 0.0% |
| Q1 2023 | $588 | +140.0% | 6,474 | 0.0% | 0.00% | +200.0% |
| Q4 2022 | $245 | -99.8% | 6,474 | +17.2% | 0.00% | 0.0% |
| Q3 2022 | $138,000 | -27.7% | 5,524 | -12.2% | 0.00% | 0.0% |
| Q2 2022 | $191,000 | -4.5% | 6,292 | +2.7% | 0.00% | 0.0% |
| Q1 2022 | $200,000 | +525.0% | 6,124 | +389.9% | 0.00% | – |
| Q4 2021 | $32,000 | -90.7% | 1,250 | -63.7% | 0.00% | -100.0% |
| Q3 2021 | $345,000 | -44.6% | 3,439 | -22.0% | 0.00% | -50.0% |
| Q2 2021 | $623,000 | +268.6% | 4,408 | +159.3% | 0.00% | +300.0% |
| Q1 2021 | $169,000 | -19.5% | 1,700 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $210,000 | +24.3% | 1,700 | -2.5% | 0.00% | 0.0% |
| Q3 2020 | $169,000 | +4125.0% | 1,743 | +6872.0% | 0.00% | – |
| Q2 2020 | $4,000 | -33.3% | 25 | -39.0% | 0.00% | – |
| Q1 2020 | $6,000 | -40.0% | 41 | -18.0% | 0.00% | – |
| Q4 2019 | $10,000 | +150.0% | 50 | 0.0% | 0.00% | – |
| Q3 2019 | $4,000 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $76,391,000 | 14.09% |
| Opaleye Management Inc. | 330,000 | $8,702,000 | 1.85% |
| Highlander Partners, L.P. | 27,600 | $728,000 | 0.89% |
| Ikarian Capital, LLC | 200,000 | $5,274,000 | 0.79% |
| Integral Health Asset Management, LLC | 103,000 | $2,716,000 | 0.75% |
| KRS Capital Management, LLC | 32,841 | $866,000 | 0.74% |
| Ghost Tree Capital, LLC | 55,000 | $1,450,000 | 0.52% |
| MADDEN SECURITIES Corp | 39,312 | $1,037,000 | 0.49% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $801,000 | 0.47% |
| Ikarian Capital, LLC | 100,000 | $2,637,000 | 0.39% |